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Summary The presence of a number of regulatory peptides (bombesin, gastrin, glucagon, somatostatin,
calcitonin and ACTH) was compared in 30 typical carcinoid tumours and 27 well differentiated neuroendoc-
rine carcinomas (atypical carcinoids) using conventional immunocytochemistry. Strong immunostaining for
one or more peptide was observed in 97% of the typical carcinoids (29/30) whereas only 67% of the
neuroendocrine carcinomas showed immunoreactivity. The peptide most frequently detected in typical
carcinoids was bombesin (67%), while gastrin was more common in neuroendocrine carcinomas (44%).
Immunoreactivity for more than one peptide was present in 33 tumours and in three cases, six different
peptides were detected.
The study shows that immunoreactivity to various peptides is more common in typical carcinoids than well
differentiated neuroendocrine carcinomas. The significance of these findings is discussed.
Lung tumours particularly small cell carcinoma and carci-
noid tumours are noted for their ability to produce peptide
hormones (Shalet et al., 1979). Previous studies have tended
to concentrate on typical carcinoids (Warren et al., 1984) but
it has recently become apparent that up to 50% of bronchial
carcinoid tumours (well differentiated neuroendocrine carci-
noma) may show atypical features. It is important therefore
to include such tumours when studying hormone production.
A series of carcinoid tumours were studied with antisera to
bombesin, gastrin, glucagon, somatostatin, calcitonin and
ACTH to evaluate the frequency of peptide production in
typical and well differentiated neuroendocrine carcinoma.
Materials and methods
This study was carried out on 57 cases of bronchial carci-
noid tumours diagnosed at the Regional Cardiothoracic
Centre, Wythenshawe Hospital, Manchester, between 1961
and 1986. The identification and diagnosis of these tumours
was based initially on the histologic appearance in sections
stained by haematoxylin and eosin and the Grimelius
method to demonstrate argyrophilia. The tumours were fixed
in 10% neutral buffered formalin for at least 24h, routinely
processed and embedded in paraffin wax. The diagnosis of
atypical carcinoid (well differentiated neuroendocrine carci-
noma) was based on the presence of one of the following
factors; tumour necrosis, nuclear pleomorphism, an increased
mitotic count, undifferentiated growth pattern, vascular and
lymphatic invasion (Hasleton et al., 1986). Frequently these
features coexisted in any one case. Between one and three
tumour blocks were selected for immunohistochemistry and
5pm thick serial paraffin sections were cut. All the cases
were stained by the peroxidase-antiperoxidase (PAP) method
or the indirect method (Sternberger, 1979).
Sections were deparaffinized in xylene, transferred to
alcohol and incubated in 0.5% hydrogen peroxide in metha-
nol for 20min to block endogenous peroxidase. They were
then rinsed in tris-HCl buffered saline, and overlayered with
normal swine serum at 1/50 dilution for 20min to reduce
background staining. The following primary rabbit antisera
were used at the following dilutions: anti-gastrin (GS) 1/500,
anti-glucagon (GLU), anti-somatostatin (SM) and anti-
Correspondence: P.S. Hasleton, Histopathology Department,
Pathology Department, Wythenshawe Hospital, Manchester M23
9LT, UK.
*Present address: Immunotherapy Unit, London Bridge Hospital,
Tooley Street, London SEI, UK.
bombesin (BN) 1/400, anti-calcitonin (CL) 1/200. The rabbit
anti-bombesin antiserum was kindly provided by the Depart-
ment of Chemical Endocrinology, St Bartholomew's Hospi-
tal, London. This antiserum recognises the C-terminal region
of bombesin, cross-reacting 70% with synthetic porcine GRP
and its C-terminal fragment, GRP (14-27) (Price et al.,
1983). The other antibodies except ACTH described below
were purchased from the DAKO corporation, Denmark.
The swine anti-rabbit IgG serum and the peroxidase anti-
peroxidase complex were diluted 1/50 and 1/200 respectively.
The sections were incubated with the first antibody overnight
for 18h at 4°C, and then sequentially with the swine anti-
rabbit and the peroxidase anti-peroxidase at their optimal
dilutions for 1 h each at room temperature. After incubation
with each antibody, the sections were rinsed in three changes
of 0.1 Mtris-HCl buffered saline (TBS) pH 7.6, 10 min each.
All the antisera were diluted with the same buffer to which
had been added 0.3% bovine serum albumin. The reaction
was developed with a freshly prepared solution of 5mg 3-3'
diaminobenzidine tetraydrochloride (DAB) in 10ml of 0.2M
tris-HCI buffer, to which 100ul of 1% hydrogen peroxide in
distilled water was added just before use. The slides were
rinsed in TBS, counterstained with Mayer's haematoxylin,
dehydrated, cleared and mounted with DPX.
The production and characterisation of the four monoclo-
nal antibodies (MAbs) to ACTH have been described pre-
viously (White et al., 1985). Briefly MAbs IA12 and lDl
were derived from immunisation with ACTH (1-24) conju-
gated to bovine serum albumin. MAbs 2A3 and 3HQ were
derived from immunisation with ACTH (1-39) conjugated to
thiolated IgG. Their specificity was assessed using human
pituitary ACTH (1-39) (National Institute of Biological
Standards Code 74/555, ACTH content 6.2 IU/ampoule:
25pg) and fragments of ACTH (White et al., 1985). For
immunocytochemistry MAbs 1A12 and lDI were used with-
out dilution. MAbs 2A3 and 3H9 were diluted 1/50 and 1/
500 respectively. After incubation with the MAb, the
sections were washed with TBS and incubated with rabbit
antimouse IgG peroxidase conjugate (Dako) diluted 1/50 for
30min at room temperature. DAB was used as a substrate
and the sections stained as described above.
Reactivity of the antibodies was confirmed by specific
distribution of stained cells in positive tissue controls which
included normal pancreas for glucagon and somatostatin,
duodenum for gastrin, medullary carcinoma of the thyroid
for calcitonin, human foetal lung for bombesin and normal
human pituitary for ACTH. Negative controls were carried
out by replacing the primary antibody with normal rabbit
serum on a section of each tumour. The results of staining
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were scored (negative to 4+) on the basis of the relative
number of tumour cells reactive for each peptide, (1 + =less
than 20 positive cells/section, 2 + =20-50 positive cells/
section, 3 + = >50 positive cells/section 4+ =all tumour cells
positive). The distribution of immunoreactive cells was
regarded as diffuse when the positive cells were seen
throughout the tumour, and as focal when they were present
as single cells or small aggregates and confined to small
areas in the section. The site of the tumour, sex and age of
the patient were noted.
Results
The 57 carcinoid tumours studied were divided according to
their histological features into 30 (53%) typical carcinoids
and 27 (47%) well differentiated neuroendocrine carcinomas
(atypical carcinoids). Forty three tumours were central and
12 peripheral, two cases were of unknown site. The ratio of
number of males to females was 29:24, in four cases the sex
was not known. The mean age was 50 years (range 18-75)
for males and 55 years (range 36-75) for females.
The results of immunohistological staining are summarized
in Table I. Forty-seven of the 57 cases (83) showed immu-
noreactivity. Among the positive cases, 14 demonstrated
reactivity for one peptide only and 11 for two. Ten cases
stained for three peptides. A small number of tumours
demonstrated multiple hormone reactivity, seven staining for
four peptides, five for five peptides. The most frequently
identified hormone in the 47 positive cases was BN in 30
tumours followed by GS (27) and CL (26), ACTH (24), SM
and GLU (19 and 16 respectively).
The coexistence of the peptides with each other, and the
degree of positive immunoreactivity in the 57 carcinoids is
illustrated in Tables II and III. BN was identified in 30
(53%) cases and in 4 cases was the only peptide present. The
staining was focal in 18 tumours and diffuse in 12. The
majority of the positive cases showed a large number of BN
immunoreactive cells (Figure 1). However in only two cases
did almost all tumour cells stain for this peptide. In one of
these most of the mucosa adjacent to the tumour was
replaced by positively stained tumour cells. In two cases
positive for both BN and CL, only single cells stained and
comparison of the sections stained for each peptide indicated
that BN and CL, were apparently produced by different
tumour cells.
Calcitonin immunoreactivity was present in 26 cases (46%)
(Figure 2). Intensity of staining varied between different
cases and also between the positive cells within each tumour.
Focal groups of tumour cells showed stronger reactivity than
those with the diffuse pattern. 15/57 cases showed bone
formation. In seven of these there was diffuse positive
staining for CL and small foci of cells with more intense
staining were seen in some of them. The remaining six cases
showed focal staining only. Two carcinoids with bone forma-
tion were negative for CL.
Positive staining for GS was demonstrated in 27 cases
(47.4%). In the majority of these, GS immunoreactive cells
predominated and were distributed evenly throughout the
tumour (Figure 3). Only a small number of cases showed
single groups of positive cells. SM immunoreactivity was
seen in 19 cases (33%), where either intensely staining cells
were a minority, being randomly scattered in the tumour or
diffuse staining of most tumour cells was visible.
Sixteen tumours (28%) were positive for glucagon, the
staining being focal in 6 cases and diffuse in 10. Glucagon
was not found as the only peptide in any of the cases
studied.
Of the four monoclonal antibodies used for the identifica-
tion of ACTH only 2A3 and 3H9 demonstrated positive
immunostaining and there was no difference in the pattern
of staining using these two MAbs. Immunoreactivity was
Table I Immunohistologic staining in 57 bronchopulmonary carcinoid tumours
Well differentiated
Typical carcinoids neuroendocrine carcinomas
No. No.
tumours with tumours with
positive positive
staining Percentage staining Percentage
Tumours studied 30 53 27 47
Positive 29 97 18 67
Negative 1 3 9 33
BN
immunoreactivity 20 67 10 37
CL
immunoreactivity 17 57 9 33
ACTH
immunoreactivity 17 57 7 26
GS
immunoreactivity 15 50 12 44
SM
immunoreactivity 13 43 6 22
GLU
immunoreactivity 13 43 3 11
BN Bombesin, CL Calcitonin, GS Gastrin, SM Somatostatin, GLU Glucagon.
Table II The coexistence of peptides in bronchopulmonary carcinoid tumours
Bombesin Calcitonin Gastrin ACTH Somatostatin Glucagon
Bombesin (4) 18 18 15 14 12
Calcitonin 18 (3) 14 13 12 13
Gastrin 18 14 (3) 13 9 12
ACTH 15 13 13 (1) 13 9
Somatostatin 14 12 9 13 (3) 11
Glucagon 12 13 12 9 11 (-)
aFigures in brackets are the number of cases positive for one peptide only.764 N. AL-SAFFAR et al.
Table III The degree of immunostaining and the distribution of
immunoreactive cells
Peptides Negative I +F F 2+D F 3+D F 4+D
Bombesin 27 5 3 1 10 9 - 2
ACTH 33 9 4 - 4 4 - 3
Calcitonin 31 5 4 2 6 9
Gastrin 30 5 3 2 5 12
Somatostatin 38 4 4 - 3 8
Glucagon 41 1 3 - 2 10
F focal pattern, D diffuse pattern 1 + is <20 cells positive, 2+ is
20-50 cells positive, 3+ is >50 cells positive, 4+ is when all tumour
cells are positive.
present in 24 tumours (42%) (Figure 4), being focal in 17
and diffuse in 7. In this latter group three tumours showed
staining of nearly every cell.
Normal bronchial tissue, containing sero-mucous glands
and epithelium adjacent to the tumour, was present in
sections from the majority of the central tumours studied.
None of the cases showed positive staining for GS in the
sero-mucous glands. However, antibodies to BN, CL, SM,
GLU and ACTH demonstrated immunoreactivity in a vari-
able number of serous and mucous glands (Figure 5).
Peptide containing basal cells were seen in the epithelium in
a small number of cases. The most commonly identified
peptides were BN (Figure 6) and CL. A large number of GS
and SM positive cells were seen in two cases. In one, both
the tumour and bronchial epithelial cells were positive for
GS, whereas in the other, where SM positive cells were
present in bronchial epithelium, tumour cells were negative
for this peptide. Basal peptide containing cells in the bron-
chial epithelium stained intensely but were less frequent than
in glands. A relatively large number of peptide producing
cells in metaplastic squamous epithelium was seen in one
case where BN and CL were identified in the same areas of
the section, but in apparently different cells. BN positive
cells were more frequent than CL positive cells but tumour
cells in this case were negative for both BN and CL. ACTH
was identified in the adjacent epithelium in only one case.
Discussion
Bronchial carcinoid tumours display immunoreactivity to a
wide range of hormones and peptides and our results
confirm this in that 47 of the 57 cases studied (83%) showed
positivity for at least one of the peptides studies. Twenty two
of the positive cases showed immunoreactivity for 3 to 5
peptides which indicated the capability of these tumours for
synthesizing and storing more than one peptide simulta-
neously. This feature has been described previously in
normal neuroendocrine cells (Larsson, 1980) and bronchial
carcinoids (Yang et al., 1983; Warren et al., 1984). In a
study of 25 bronchopulmonary carcinoids, Warren et al.
(1984) have demonstrated up to eight hormones and their
findings were supported by ultrastructural identification of a
heterogeneous population of neurosecretory granules within
single tumour cells. Multihormonal production has also been
reported in small cell lung carcinoma cell lines which can
secrete up to ten different peptides (Sorenson et al., 1981).
The most frequently identified hormones in this study
were bombesin (30 cases) followed by gastrin and calcitonin
(27 and 26 cases) respectively. The finding of positive
immunoreactivity for gastrin in a large number of our
tumours is in contrast to three other studies which could not
demonstrate the presence of gastrin (Yang et al., 1983;
Tamai et al., 1983 & Martensson et al., 1987). However,
Warren et al., (1984) found gastrin in 15/25 (60%) bronchial
carcinoids studied. Although there is no clear explanation
for these results it could relate to the ability of the antisera
to recognise the various molecular forms such as Gastrin 1-
17, 1-34, 1-14 and 1-5 (Walsh & Grossman, 1975).
The results of immunostaining for bombesin are in agree-
ment with previous reports. We observed immunoreactivity
in 67% of typical carcinoids and 37% of atypical carcinoids
in comparison with the study by Hamid et al. (1987) which
showed moderately strong immunostaining in 35% of benign
carcinoids and 22% of atypical carcinoids. The difference in
the prevalence could relate to a difference in the specificity
of the antisera, but this cannot be confirmed because the
relevant specificity is not detailed in their study, and it may
anyway relate to a difference in the ability of the antisera to
recognise their epitopes in the precursor molecule. The
relative immunoreactivity for bombesin was confirmed in the
series of Hamid et al. (1987) by radioimmunoassay of
tumour extracts from paraffin blocks suggesting that the
immunostaining is a reliable approach for examining the
expression of bombesin in bronchopulmonary carcinoids.
Since high levels of bombesin have been reported in cell lines
from small cell lung cancer (Moody et al., 1981; Wood et al.,
1981; Sorenson et al., 1982) and in pulmonary carcinoid
tumours (Bostwick et al., 1984; Martensson et al., 1987).
Calcitonin, a 29 amino acid peptide, is predominantly
found in thyroid C-cells and their derivative tumour,
medullary carcinoma. In this study calcitonin was found in
46% of bronchopulmonary carcinoids. This is more frequent
than recent reports where Warren et al. (1984) showed
calcitonin immunoreactivity in 8% of bronchial carcinoids
and Martensson et al. (1987) in 22% whereas Yang et al.
(1983) were unable to demonstrate reactivity in seven
tumours. Eighteen of the 26 cases with immunoreactivity for
calcitonin in the present study were also positive for bombe-
sin. The frequent demonstration of bombesin and calcitonin
in our series parallels previous studies of normal endocrine
cells of the bronchopulmonary tree (Cutz et al., 1981) and
bronchopulmonary carcinoids (Warren et al., 1984), and in
normal and neoplastic thyroid C-cells. The finding of bom-
besin and calcitonin in separate cells in this study could
indicate that the hormones are not co-secreted. The other
frequent combinations of peptides in our series were gastrin
and bombesin (18 cases), bombesin and ACTH (15 cases)
and gastrin and calcitonin (14 cases).
ACTH was absent in the cases described by Warren et al.
(1984) but was seem in 28% of tumours in the study of
Martensson et al. (1987). In common with these authors the
present study shows ACTH was the second commonest
pattern of immunostaining shown in bronchopulmonary
carcinoids. The differences between these studies could well
be due to the antibodies used, Warren et al. (1984) used
Porcine anti-ACTH 1-39 antibodies at a dilution of 1/400,
Martensson et al. (1987) used ACTH antisera at a dilution
of 1/160 obtained from MILAB, Malmo, Sweden.
There is a suggestion that the production of calcitonin in
bronchopulmonary carcinoid tumours may induce ossifica-
tion of bronchial cartilage as well as bone formation in the
tumour (Cooney et al., 1979). Fifteen (26%) of the tumours
in our study showed bone formation, 13 of which were
positive for calcitonin. However, a further 12 positive cases
showed no bone suggesting that no such correlation exists. It
is not logical to expect calcitonin to induce ossification since
bone is rare in medullary carcinoma of thyroid, which has
high levels of calcitonin. Calcification and the presence of
psammoma bodies have been reported in this tumour (Wil-
liams et al., 1966).
Well differentiated neuroendocrine carcinomas ('atypical
or malignant carcinoids') did not stain positively as fre-
quently as typical carcinoids. One third of the neuroendoc-
rine carcinomas were negative for hormones as opposed to
3% of the typical carcinoids. Somatostatin and glucagon
were found least and bombesin was found most often. One
reason for lack of staining could be that the less well
differentiated neuroendocrine carcinomas produce either
smaller peptides or smaller quantities of peptides.
Finally it may be asked what is the clinical relevance of
the peptide production demonstrated in this study. Only
three cases showed clinical effects of hormone release; twoIMMUNOREACTIVITY OF PEPTIDES IN BRONCHIAL CARCINOIDS 765
Figure 4
Figure 5 Figure 6
Figure 1 Typical carcinoid staining strongly to bombesin (Immunoperoxidase x250).
Figure 2 Atypical carcinoid tumour with strong positive staining for calcitonin (Immunoperoxidase x 250).
Figure 3 Typical carcinoid with almost all tumour cells staining for gastrin (Immunoperoxidase x400).
Figure 4 Atypical carcinoid. Focal positive staining for ACTH with MAb 3H9 (Immunoperoxidase x 250).
Figure 5 Immunoreactivity to calcitonin at bronchial resection margin in mucous gland (Immunoperoxidase x 250).
Figure 6 Epithelial cells staining for bombesin in the epithelium of resection margin of a bronchial carcinoid.
(Immunoperoxidase x400).766 N. AL-SAFFAR et al.
had the carcinoid syndrome and one showed features of
ectopic growth hormone production (Shalet et al., 1979).
However, this study covers a period of 25 years and it is
likely that endocrine manifestations were missed in the early
years. Despite this it still appears there is a disparity between
the clinical manifestations of bronchial carcinoid tumours
and the large number of cases showing immunoreactivity.
One explanation is that the pulmonary endothelial cells can
detoxicate or degrade hormones so they do not reach the
systemic circulation.
It should finally be noted that non-small cell carcinoma
tumours can secrete hormones. Mooi et al. (1988) have
shown in 11 cases, classified as large or squamous cell
carcinoma, positive staining for neuron specific enolase,
protein gene product 9.5 and C-terminal peptide of human
pro-bombesin and chromogranin.
Dr Al-Saffar had a Post Doctoral Visiting Fellowship at the
Paterson Institute, Christie Hospital, Manchester. Dr A. White is
funded by the North West Regional Health Authority.
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